Venus Remedies
VENUSREMNSE

Venus Remedies

₹896.6035.55 (4.13%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
831.10
Today’s high
904.10
52 week low
285.70
52 week high
944.75
Open price
833.60
Previous close
861.05
Live volume
94,779
Lower circuit
851.80
Upper circuit
941.40

Fundamentals

Market Cap
₹1,200Cr
ROE
10.66%
P/E Ratio(TTM)
15.72
EPS(TTM)
57.09
P/B Ratio
2.02
Dividend Yield
0.00%
Industry P/E
31.31
Book Value
444.61
Debt to Equity
0.02
Face Value
10

Financials

*All values are in Rs. Cr
No Graph Data To Display
Quarterly
Yearly

About

Venus Remedies Limited is a research-driven Indian pharmaceutical company with a global presence, specializing in the injectables space. The company's core vision is to leave a positive footprint on human health by creating an institution that transcends the mortal being. A key part of its Mission 2026 is to foster innovative therapies that target the major health challenge of Antimicrobial Resistance. It develops solutions for human ailments in critical areas like oncology, neurology, pain management, and also has a herbal product portfolio. The company's priority regions are the Middle East, South-East Asia, Africa, and Latin America, where it aims to be a partner of choice. With over 1040 marketing authorisations and more than 25 GMP approvals, the company has expanded its boundaries to over 90 countries.;
MD/CEO
Pawan Chaudhary
Founded in
1989
NSE symbol
VENUSREM
Industry

Shareholding Pattern

Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Retail And Others
54.96%
Promoters
41.76%
Foreign Institutions
2.26%
Other Domestic Institutions
1.03%

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
Innova CaptabINNOVACAP
₹704.40
+0.45 (0.06%)
L
    H
    4,025.7730.43.94
    ₹388.25
    -4.50 (1.15%)
    L
      H
      3,640.7240.624.99
      Aarti DrugsAARTIDRUGS
      ₹352.70
      +6.30 (1.82%)
      L
        H
        3,213.1615.872.19
        ₹288.60
        -0.10 (0.03%)
        L
          H
          2,905.6958.074.6
          Livesquawk
          Venus Remedies reports Q3 net profit of ₹256M, up from ₹196M YoY. Q3 revenue rose to ₹1.8B, compared to ₹1.77B YoY.
          Livesquawk
          Venus Remedies receives ₹11.8 Cr under PLI scheme after ₹10 Cr earlier.
          Livesquawk
          Venus Remedies resolves all pending income tax issues, removing ₹33.4 crore contingent liability. The company also obtained refunds for protest deposits.
          2026
          29
          Jan
          Quarterly Result
          Release date
          2025
          10
          Nov
          Quarterly Result
          Release date
          1
          Aug
          Quarterly Result
          Release date
          Events calendar
          View upcoming events in other stocks